Form 4: BioCardia CEO Peter Altman Increases Stake in BCDA

BioCardia, Inc. President and CEO Peter Altman purchased 1,000 shares of common stock across two transactions.

Summary

• Peter Altman, President and CEO of BioCardia, Inc., acquired a total of 1,000 shares of common stock.
• The purchases occurred on April 20, 2026 (600 shares) and April 21, 2026 (400 shares).
• The weighted average purchase price for both transactions was $1.23 per share.
• Following these transactions, Mr. Altman's total beneficial ownership increased to 275,766 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mildly positive signal, as it reflects executive confidence through personal capital commitment, though the transaction size is modest.

Positives

• Insider confidence is demonstrated by the CEO increasing his equity position in the company.
• The purchase was made at market prices, signaling alignment with shareholder interests.

Negatives

• The volume of shares purchased (1,000) is relatively small compared to the total holdings of 275,766 shares.

Risks

• The company remains subject to market volatility and the inherent risks associated with the biotechnology sector.

Future Outlook

No specific forward-looking guidance was provided in this filing.

Industry Context

StockSavvy.ai notes that insider buying in the biotechnology sector is often viewed as a positive signal of management's belief in the company's long-term clinical or commercial prospects.

Comparison to Industry Standards

• Insider buying is a standard practice for executives to signal confidence, consistent with behavior seen in small-cap biotech firms.

Stakeholder Impact

• Shareholders may interpret the CEO's purchase as a sign of stability and confidence in the company's direction.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Recommendation

While insider buying is a positive indicator, the small volume of the purchase is unlikely to significantly alter the investment thesis or share price trajectory on its own.

Keywords

BioCardia, BCDA, Insider Trading, Form 4, Biotech, Equity Ownership